	US 12,351,826 B2
	Method to produce conditionally apoptotic cells
Filippo Rossignoli, Verona (IT); Carlotta Spano, Modena (IT); Giulia Grisendi, Reggio Emilia (IT); Olivia Candini, Crevalcore (IT); and Massimo Dominici, Ferrara (IT)
Assigned to RIGENERAND S.R.L., Medolla (IT)
Appl. No. 17/058,911
Filed by EIR BIOTHERAPIES SRL, Mirandola (IT)
PCT Filed May 31, 2019, PCT No. PCT/IT2019/050123 § 371(c)(1), (2) Date Nov. 25, 2020, PCT Pub. No. WO2019/229782, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 102018000005951 (IT), filed on Jun. 1, 2018.
Prior Publication US 2021/0214689 A1, Jul. 15, 2021
Int. Cl. C12N 5/0775 (2010.01); C12N 15/63 (2006.01)

CPC C12N 5/0667 (2013.01) [C12N 15/63 (2013.01); C12N 2740/15043 (2013.01)]

6 Claims

1. A method to produce conditionally apoptotic cells, comprising:

modifying, with the introduction of a sequence coding a conditional suicide gene (CSG), a cell population expressing an anti-tumor soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), infected with a retroviral vector and with a human adipose tissue-derived pericytes (AD-PC) phenotype, wherein said suicide gene is iCasp9, and said cells with a pericytes (PC) phenotype are generated by tissues selected from the group consisting of adipose tissue, placenta, amniotic fluid, dental pulp, muscle tissue, cardiac tissue, umbilical cord, cutaneous tissue, pancreatic tissue, intestinal tissue, and decidual endometrial tissue.